Keymed Biosciences Inc. (HKG:2162) About To Shift From Loss To Profit
With the business potentially at an important milestone, we thought we'd take a closer look at Keymed Biosciences Inc.'s (HKG:2162) future prospects. Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The HK$26b market-cap company announced a latest loss of CN¥523m on 31 December 2025 for its most recent financial year result. Many investors are wondering about the rate at which Keymed Biosciences will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Consensus from 8 of the Hong Kong Biotechs analysts is that Keymed Biosciences is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of CN¥392m in 2026. The company is therefore projected to breakeven around 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 65%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
We're not going to go through company-specific developments for Keymed Biosciences given that this is a high-level summary, though, keep in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
Check out our latest analysis for Keymed Biosciences
Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 28% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
Next Steps:
There are key fundamentals of Keymed Biosciences which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Keymed Biosciences, take a look at Keymed Biosciences' company page on Simply Wall St. We've also compiled a list of essential factors you should further research:
- Historical Track Record: What has Keymed Biosciences' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Keymed Biosciences' board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.